Asymptomatic hyperuricemia: the case for conservative management.
The management of asymptomatic hyperuricemia is controversial. Reported benefits from treatment prevention of acute gouty arthritis, chronic tophaceous gout, urolithiasis, or gouty nephropathy. A review of experimental and clinical data suggests that the risks of asymptomatic hyperuricemia are small or unknown and the efficacy of long-term treatment in preventing gout or renal disease is unproved. The costs and risks of prolonged drug administration and practical considerations such as patient compliance mitigate against long-term therapy in asymptomatic persons. We offer some recommendations for an expectant approach to the management of asymptomatic hyperuricemia.
D006073:Gout / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007669:Kidney Calculi / Q000175:diagnosis; D012306:Risk; D014527:Uric Acid / Q000097:blood*
D014527:Uric Acid